Peroxiredoxin Ⅱ在卵巢上皮性肿瘤中的表达及其临床意义

Expression of Peroxiredoxin Ⅱ in ovarian cancer:correlation with clinicopathological features

目的探讨Peroxiredoxin Ⅱ在卵巢上皮性肿瘤组织中的表达及临床意义。方法用蛋白免疫印迹(westernblot)的方法检测71例新鲜卵巢组织及卵巢上皮肿瘤组织的Peroxiredoxin Ⅱ的表达情况,其中正常卵巢组织16例,良性卵巢肿瘤16例,卵巢癌39例。结果Peroxiredoxin Ⅱ在正常卵巢组织表达为(1.00±0.44),在良性卵巢上皮性肿瘤组织中表达为(0.83±0.50),在卵巢癌组织中表达为(0.60±0.23),卵巢癌与正常卵巢组织的表达差异有显著性(P<0.01);良性卵巢上皮性肿瘤组织与正常卵巢组织、癌组织比较差异均无统计学意义;且Peroxiredoxin Ⅱ在卵巢癌组织表达降低与其临床分期、病理类型、细胞分化及绝经等参数无关。结论Peroxiredoxin Ⅱ可能在卵巢上皮癌的发生中起抑制因子作用,而在其发展中无明显作用。

[Objective] To investigate the significance of Peroxiredoxin Ⅱ expression with carcinogenesis and progression in ovarian cancer. [Method] Western blot was used to investigate the expression of Peroxiredoxin Ⅱ in 16 cases of nomal ovarian tissue, 16 cases of benign ovarian tumor, and 39 cases of ovarian cancer. [Result] Expression of Peroxiredoxin Ⅱ in nomal ovarian tissue （1.00±0.44） and benign ovarian tumor（0.83±0.50） was higher than that in ovarian cancer （0.63±0.23）. There was a significant difference in the expression of Peroxiredoxin Ⅱ between nomal ovarian tissue （1.00±0.44） and ovarian cancer 0.63±0.23） （P 〈0.05）. There was no relationship between the expression of Peroxiredoxin Ⅱ and clinicopathological parameters, including cilical stage, tumor cell differentiation degree, histopathologic classification, and menopause. [ Conclusion] Peroxiredoxin Ⅱ highly expressed in normal ovarian tissue and benign ovarian tumor while low expressed in ovarian cancer. Our findings suggest that high expression of Peroxiredoxin Ⅱ may play an important role as a suppressor factor in carcinogenesis in ovarian tumor not in tumor progression in ovarian cancer.